RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology ...

Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer, extending median overall survival to ...

NHWD-870 HCl achieves 45% response rate in thoracic NUT carcinoma, nearly doubling the overall cohort's 30% rate in advanced ...

ASP-1929 + Pembrolizumab achieved 28.2-month median OS in recurrent/metastatic HNSCC, with 35% alive at four years in Phase ...

FDA AI Guidance requires clinical trial sponsors to validate algorithms before submission, shifting documentation and testing ...

Lilly's sofetabart mipitecan achieves 79% response rate in platinum-sensitive ovarian cancer patients, including those with prior PARP inhibitor exposure.

A Nature Neuroscience study separates psilocybin's neuroplastic effects from its hallucinogenic ones, and it should reshape ...

WCG's Activation Intelligence targets clinical trial rework by catching document conflicts before activation, saving sites ...

OD-001 Phase 2a ulcerative colitis study hits primary endpoint with 2.4-point modified Mayo score reduction at Week 12, ...

NFL funds $500K study into elevated ALS risk in athletes, veterans, and first responders to identify genetic and biological ...

MA beneficiaries received kidney transplants at nearly half the rate of traditional Medicare patients post-Cures Act, a ...

Upacicalcet meets primary endpoints in Phase 3 trials for secondary hyperparathyroidism, with 42–44% of patients achieving 30% PTH reduction versus 17% on place ...